Venture philanthropy

 Landmark victory for individuals living with DEB and their families, the FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB).

Retrieved on: 
Friday, May 19, 2023
FDA, Pharmaceutical, Business, General Health, Professional Services, Philanthropy, Genetics, Clinical Trials, Fund Raising, Foundation, Biotechnology, Science, Other Philanthropy, Other Science, Research, Health, SAB, Yale University, Skin, DEB, Krystal, Parent, RDEB, The Butterfly Children, Epidermolysis bullosa, Multimedia, MIT, Venture philanthropy, Physician, Harvard Business School, EB, First Ever, Medical device, Pharmaceutical industry

Today, DEB warriors around the world cross into the 5% with the approval of Krystal Biotech’s VYJUVEK™ treatment.

Key Points: 
  • Today, DEB warriors around the world cross into the 5% with the approval of Krystal Biotech’s VYJUVEK™ treatment.
  • This FDA approval marks a milestone in EBRP’s mission to discover treatments and a cure for EB.
  • We are grateful for Krystal Biotech’s commitment to delivering the first ever FDA approved treatment for DEB.
  • Today’s FDA approval of the first-ever medication to treat DEB is an exciting milestone on this journey.

Parent Project Muscular Dystrophy Invests $500,000 in Myosana Therapeutics to Advance Non-Viral Gene Therapy Platform

Retrieved on: 
Wednesday, January 25, 2023
Safety, Therapy, Transgene, Male, DMD, PPMD, Heart failure, Drug development, Duchenne muscular dystrophy, Venture philanthropy, Investment, AAV, Muscular dystrophy, Vaccine, Pharmaceutical industry, Becker, Duchenne

WASHINGTON , Jan. 25, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $500,000 programmatic investment in Myosana Therapeutics, Inc. (Myosana) to support the company's continuing development and translation of a non-viral gene therapy delivery platform aiming to slow skeletal muscle degeneration and heart failure in Duchenne.

Key Points: 
  • Duchenne is the most common muscular dystrophy in children, affecting approximately one in 5,000 live male births.
  • It is a progressive disorder that causes muscles to become weaker over time until it affects the whole body.
  • Duchenne is caused by a change in the DMD gene that codes for the dystrophin protein.
  • PPMD previously announced a $350,480 programmatic investment in Myosana in August 2021, to support the development of its non-viral gene therapy candidate that could potentially deliver full-length dystrophin systemically.

Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS

Retrieved on: 
Tuesday, January 17, 2023
Venture philanthropy, Neurodegeneration, Entrepreneurship, MVP, Muscular Dystrophy Association, Doctor of Philosophy, Biomedical engineering, MDA, Motor neuron, Amyotrophic lateral sclerosis, Degenerative disease, Muscular dystrophy, CERF, EFS, ALS, NIH, Pharmaceutical industry

BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).

Key Points: 
  • BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).
  • MDA uses the Venture Philanthropy program to invest in companies committed to clinical application of high-impact, novel treatments for neuromuscular diseases, including ALS.
  • This funding will support the launch of an ALS early feasibility study (EFS) using PathMaker’s breakthrough technology for motor neuron hyperexcitability suppression.
  • To learn more about the Muscular Dystrophy Association and the MVP program, please visit https://www.mda.org/science/mda-venture-philanthropy .

Billie Eilish, Will Ferrell, Tom Holland, John Legend, Chris Pratt, Keanu Reeves, Olivia Rodrigo, Emma Watson, and more, help lead year 3 of Venture Into Cures which in total has raised over $6 million for EB Research Partnership, to find a cure for Epide

Retrieved on: 
Thursday, December 1, 2022
Venus, Marketing, Human, Skin, Jonas Brothers, The Butterfly Children, Door knocker, Organization, How I Braved Anu Aunty and Co-Founded a Million Dollar Company, Epidermolysis bullosa, Multimedia, FINNEAS, Parent, Frog, Pulse, EB, Research, Broken Social Scene, Venture philanthropy, Bigger Love, CSR, FDA, Music, Pharmaceutical industry, Film, Macklemore

The one-hour virtual show was produced by EBRP and Door Knocker Media, with artist booking by one twenty eight.

Key Points: 
  • The one-hour virtual show was produced by EBRP and Door Knocker Media, with artist booking by one twenty eight.
  • "Through the ongoing support of the Venture Into Cures' audience, donors and the patient and medical communities, we will continue to fund the most innovative and impactful global research.
  • Singer/songwriter John Legend,performing an exclusive presentation of his song, "Never Break", in honor of the brave young people and families living with EB.
  • Actor Chris Pratt introduces seven year old EB warrior Solomon Bonner, and shares his story through a mutual love of dinosaurs.

Macklemore, Lamorne Morris, Keanu Reeves, and Emma Watson join Jill and Eddie Vedder, and more, for a virtual benefit show support for EB Research Partnership's mission to find a cure for Epidermolysis Bullosa

Retrieved on: 
Thursday, November 17, 2022
EB, The Butterfly Children, Epidermolysis bullosa, Friends, Family, Research, Skin, FDA, Venture philanthropy, Pharmaceutical industry, Macklemore

The show will feature moving stories about individuals and families living with Epidermolysis Bullosa (EB), alongside celebrity appearances and performances, to educate viewers about EB and raise critical funds to support a cure for EB and other rare diseases.

Key Points: 
  • The show will feature moving stories about individuals and families living with Epidermolysis Bullosa (EB), alongside celebrity appearances and performances, to educate viewers about EB and raise critical funds to support a cure for EB and other rare diseases.
  • "This year, we're continuing to rally our friends and family around the cause, with my daughters Olivia and Harper joining the show."
  • Over the last ten years, EBRP in particular has made incredible strides in research and clinical trials.
  • Please join us in achieving that goal and changing lives across the globe," added Eddie Vedder, musician and EBRP co-founder.

SafeMoon V2 is Now Trading on the Mandala Exchange

Retrieved on: 
Tuesday, May 10, 2022
Technology, Other Philanthropy, Philanthropy, Other Technology, Cloud, Ecosystem, Insurance, BTC, Policy, Tax, KYC, Partnership, Compliance, Technology, Venture philanthropy, Defi, Growth, Decentralized finance, Cryptocurrency, Binance

Technology provider SafeMoon , creator of SafeMoon Protocol V2, a community-focused DeFi token and component of the emerging SafeMoon ecosystem, is now trading on the Mandala exchange.

Key Points: 
  • Technology provider SafeMoon , creator of SafeMoon Protocol V2, a community-focused DeFi token and component of the emerging SafeMoon ecosystem, is now trading on the Mandala exchange.
  • Traders will be taxed the standard 10% SafeMoon fee as well as a Mandala trading fee.
  • Mandala will reflect 6% of collected taxes to the SafeMoon team to distribute to their allocated addresses as per the defined liquidity pool program for v2 token holders.
  • Some key benefits of using the Mandala Exchange include: no KYC under 2 btc withdrawals, trading fees as low as 0.065%, 1100+ trading pairs, Binance's SAFU insurance policy, and multiple algorithmic bot trading integrations.

SafeMoon Appoints Video Expert Jonathan ‘Sketch’ White as Studio Manager for Company Video and Podcast

Retrieved on: 
Thursday, March 31, 2022
Environment, Technology, Finance, Public Relations, Investor Relations, Communications, Professional Services, Software, Philanthropy, Audio, Video, Other Philanthropy, Crypto, Venture philanthropy, CBS, White, Growth, Fame, Fox, History of the Oakland Raiders, ABC, CEO, Video production, Technology, 1964 NFL Draft, Ecosystem, Magic, NBC, Defi, VP, History, Pro Football Hall of Fame, Fashion, Sketch

In a move to raise the bar on high quality video content in the crypto technology realm, Crypto currency leader SafeMoon today announced the appointment of Jonathan Sketch White as Studio Manager and head of Video Production.

Key Points: 
  • In a move to raise the bar on high quality video content in the crypto technology realm, Crypto currency leader SafeMoon today announced the appointment of Jonathan Sketch White as Studio Manager and head of Video Production.
  • As Studio Manager for Goal Line Productions, Jonathan White has made the visual communications of Maddens leadership messages equal to the magic of the Madden persona itself.
  • At SafeMoon, Sketch assumes responsibility for the expanding production of the companys video content including SafeMoon podcasts and all varieties of educational production.
  • We are honored to welcome Sketch to the SafeMoon team and look forward to leveraging the tremendous talents he brings, added CEO John Karony.

SafeMoon Appoints Three New Members to its Leadership Team as the Company Moves to Next Stage

Retrieved on: 
Wednesday, March 23, 2022
Professional Services, Philanthropy, Technology, Other Philanthropy, Software, Finance, Banking, Decentralized finance, Venture philanthropy, Ethics, Growth, Cryptocurrency, CEO, CTO, South by Southwest, Ecosystem, Defi, VP, Vision, North Star, Research and development, Management, Renewable energy, Cryptography, Research, Aegis, Technology

Lynn Spraggs, Ph.D., owner of cybersecurity company Aegis Systems, Canada joins SafeMoon as Director of Cryptography.

Key Points: 
  • Lynn Spraggs, Ph.D., owner of cybersecurity company Aegis Systems, Canada joins SafeMoon as Director of Cryptography.
  • Robert Spraggs, CTO of Aegis, assumes the role of Director of Technology.
  • Scientist and futurist, technology architect, and social/environment impact creator Jake Hammock joins the company as VP of Research and Development.
  • We appreciate and value the contributions of everyone involved with SafeMoon through the amazing growth and progress weve experienced from our inception, said Karony.

SafeMoon Advances the Broadening Conversation on ‘Return on Impact’ at SxSW and March 24, 2022, NGOCSD-NY, UN We Need Event

Retrieved on: 
Monday, March 21, 2022
Technology, Other Philanthropy, Philanthropy, Other Technology, Venture philanthropy, NGO Committee on the Status of Women, New York, Organization, Return, RSVP, Blockchain, Growth, Kate Porter, EDT, Business Insider, CEO, South by Southwest, Woman, Sustainability, Technology, Friction, Ecosystem, Defi, Coalition, HR, CNBC

Technology ecosystem leader SafeMoon is initiating and broadening the conversation around venture philanthropy and Return on Impact the ability to advance social impact in the fastest and most effective possible ways.

Key Points: 
  • Technology ecosystem leader SafeMoon is initiating and broadening the conversation around venture philanthropy and Return on Impact the ability to advance social impact in the fastest and most effective possible ways.
  • Specifically, SafeMoon is embodying the ability to create bigger and broader humanitarian impacts through blockchain and crypto technology, removing many aspects of the friction that make traditional development time-consuming and costly.
  • Readers can hear Karonys remarks and podcast appearances through the Grit Daily News YouTube channel, available here .
  • The event, and Porters presentation, will also be available following the March 24 event through a link that SafeMoon will later provide via SafeMoon.com.

SafeMoon CEO John Karony Named a 2022 CEO of the Year by Utah Business

Retrieved on: 
Thursday, March 10, 2022
Technology, Other Philanthropy, Philanthropy, Other Technology, Goal, Kate Porter, Blockchain, UN, South by Southwest, CNBC, ROI, Business Insider, Interview, Technology, Ecosystem, Female, Decentralized finance, Growth, Year, Venture philanthropy, Wind, Cryptocurrency, Renewable energy

Today, Utah Business magazine acknowledged SafeMoon CEO John Karony as a 2022 CEO of the Year.

Key Points: 
  • Today, Utah Business magazine acknowledged SafeMoon CEO John Karony as a 2022 CEO of the Year.
  • The award is especially fitting following the companys historic launch of initial technology and the SafeMoon protocol and token in 2021, which has resulted in a participating audience of multiple millions.
  • SxSW Presence at the GritDaily House on SafeMoon Saturday March 12, 2022
    This weekend John Karony and SafeMoon will be present throughout the day in live and webcast sessions during GritDailys SafeMoon Saturday podcasts, Interviews, and panels.
  • panel sessions will include live interviews of John Karony by editorial leaders including author and TV personality Robin Raskin, Sydney Bradley of Business Insider, Casey Craig of Coindesk, and Jade Scipioni of CNBC.